Recent Blog Articles
Embryo donation: One possible path after IVF
How to stay strong and coordinated as you age
Acupuncture relieves prostatitis symptoms in study
Skin in the game: Two common skin problems and solutions for men
Anti-inflammatory food superstars for every season
Harvard Health Ad Watch: An upbeat ad for a psoriasis treatment
A new targeted treatment for early-stage breast cancer?
What is neurodiversity?
Thinking about holiday gatherings? Harvard Health experts weigh in
Time to stock up on zinc?
In the news: FDA approves the first oral drug for reducing multiple sclerosis relapses
People with relapsing forms of multiple sclerosis (MS) have a new option for reducing periodic attacks (relapses) and for delaying the progression of MS-related disability. MS is typically treated with injected drugs or infusions, which can be painful and inconvenient and may discourage some patients from staying on therapy. The FDA has approved the first oral medication, fingolimod, brand name Gilenya (pronounced jil-EN-yah).
The drug, taken once a day in 0.5-milligram (mg) capsules, works by a different mechanism than other approved MS medications, and in a head-to-head comparison, it was more effective against relapses than one of the leading injectables. However, fingolimod has a number of side effects — some potentially quite serious — and its long-term safety and effectiveness are unknown.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Free Healthbeat Signup
Get the latest in health news delivered to your inbox!